![1,2-BenzenedicarboxaMide, N1,N2-bis[[(5S)-2-oxo-3-[4-(3-oxo-4-Morpholinyl)phenyl]-5-oxazolidinyl]Methyl]- 1365267-36-2 wiki 1,2-BenzenedicarboxaMide, N1,N2-bis[[(5S)-2-oxo-3-[4-(3-oxo-4-Morpholinyl)phenyl]-5-oxazolidinyl]Methyl]- 1365267-36-2 wiki](https://structimg.guidechem.com/10/46/2516325.png)
1,2-BenzenedicarboxaMide, N1,N2-bis[[(5S)-2-oxo-3-[4-(3-oxo-4-Morpholinyl)phenyl]-5-oxazolidinyl]Methyl]- 1365267-36-2 wiki
![عبدالله خربوش on Twitter: "COMPASS trial: Rivaroxaban with or without aspirin in stable CVD. The NEJM. 2017. epub 2017-08-27:1-12. Further evidence of increased major bleeding with this approach will necessitate careful consideration عبدالله خربوش on Twitter: "COMPASS trial: Rivaroxaban with or without aspirin in stable CVD. The NEJM. 2017. epub 2017-08-27:1-12. Further evidence of increased major bleeding with this approach will necessitate careful consideration](https://pbs.twimg.com/media/DpqFVGpW0AATDDu.jpg)
عبدالله خربوش on Twitter: "COMPASS trial: Rivaroxaban with or without aspirin in stable CVD. The NEJM. 2017. epub 2017-08-27:1-12. Further evidence of increased major bleeding with this approach will necessitate careful consideration
![Molecules | Free Full-Text | C-11, a New Antiepileptic Drug Candidate: Evaluation of the Physicochemical Properties and Impact on the Protective Action of Selected Antiepileptic Drugs in the Mouse Maximal Electroshock-Induced Seizure Molecules | Free Full-Text | C-11, a New Antiepileptic Drug Candidate: Evaluation of the Physicochemical Properties and Impact on the Protective Action of Selected Antiepileptic Drugs in the Mouse Maximal Electroshock-Induced Seizure](https://www.mdpi.com/molecules/molecules-26-03144/article_deploy/html/images/molecules-26-03144-g001-550.jpg)
Molecules | Free Full-Text | C-11, a New Antiepileptic Drug Candidate: Evaluation of the Physicochemical Properties and Impact on the Protective Action of Selected Antiepileptic Drugs in the Mouse Maximal Electroshock-Induced Seizure
![WO2016017993A1 - Pharmaceutical formulation comprising amorphous or thermodynamically metastable rivaroxaban - Google Patents WO2016017993A1 - Pharmaceutical formulation comprising amorphous or thermodynamically metastable rivaroxaban - Google Patents](https://patentimages.storage.googleapis.com/0f/c3/5d/4b71a96e7d171d/PCTKR2015007667-appb-I000001.png)
WO2016017993A1 - Pharmaceutical formulation comprising amorphous or thermodynamically metastable rivaroxaban - Google Patents
![Joanna Poole 💙 (@jopo_dr@critcare.social) on Twitter: "Linezolid and rivaroxaban are almost identical yet riv has no antimicrobial and linezolid has no anticoagulant activity. https://t.co/gp5Hba14fl" / Twitter Joanna Poole 💙 (@jopo_dr@critcare.social) on Twitter: "Linezolid and rivaroxaban are almost identical yet riv has no antimicrobial and linezolid has no anticoagulant activity. https://t.co/gp5Hba14fl" / Twitter](https://pbs.twimg.com/media/FFX27CIXwAYo7k0.jpg:large)
Joanna Poole 💙 (@jopo_dr@critcare.social) on Twitter: "Linezolid and rivaroxaban are almost identical yet riv has no antimicrobial and linezolid has no anticoagulant activity. https://t.co/gp5Hba14fl" / Twitter
![Oral, Direct Factor Xa Inhibitors in Development for the Prevention and Treatment of Thromboembolic Diseases | Arteriosclerosis, Thrombosis, and Vascular Biology Oral, Direct Factor Xa Inhibitors in Development for the Prevention and Treatment of Thromboembolic Diseases | Arteriosclerosis, Thrombosis, and Vascular Biology](https://www.ahajournals.org/cms/asset/585a04a4-457a-4d86-93ee-9b64e0f03b02/5ff1.jpg)